Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

Affiliations

• ¹ Hospital Universitario de Salamanca, Spain; University of Salamanca. mvmateos@usal.es.
• ² University Hospital Hamburg-Eppendorf, Hamburgo.
• ³ National and Kapodistrian University of Athens, Medicine School, Athens, Greece.
• ⁴ Evangelismos General Hospital, Athens, Greece.
• ⁵ University of Bologna.
• ⁶ University Hospital Leuven, Leuven.
• ⁷ Hospital Universitario Marques de Valdecilla (IDIVAL), Santander, Spain; University of Cantabria, Santander, Spain.
• ⁸ Theageneion Cancer Hospital, Thessaloniki, Greece.
• ⁹ University of Torino, Italy; AOU Citta della Salute e della Scienza of Turin.
• ¹⁰ Hopital La Mileterie.
• ¹¹ Clinica Universidad de Navarra, Pamplona. Spain; Centro de Investigacion Medica Aplicada (CIMA), Pamplona. Spain; Instituto de Investigacion Sanitaria de Navarra IDISNA, Pamplona. Spain; Centro de Investigacion Biomedica en Red en Cancer (CIBERONC) Pamplona, Spain.
• ¹² Oslo Myeloma Center, Oslo, Norway; Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
• ¹³ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seragnoli", Bologna, Italy; Universita di Bologna, Bologna.